- Home
- PD vs VRDN Comparison
PD vs VRDN Comparison
Compare PD & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PD
- VRDN
- Stock Information
- Founded
- PD 2009
- VRDN 2006
- Country
- PD United States
- VRDN United States
- Employees
- PD N/A
- VRDN N/A
- Industry
- PD Computer Software: Prepackaged Software
- VRDN Medical Specialities
- Sector
- PD Technology
- VRDN Health Care
- Exchange
- PD Nasdaq
- VRDN Nasdaq
- Market Cap
- PD 1.4B
- VRDN 1.2B
- IPO Year
- PD 2019
- VRDN N/A
- Fundamental
- Price
- PD $13.92
- VRDN $14.72
- Analyst Decision
- PD Buy
- VRDN Strong Buy
- Analyst Count
- PD 12
- VRDN 11
- Target Price
- PD $19.50
- VRDN $38.50
- AVG Volume (30 Days)
- PD 1.6M
- VRDN 714.5K
- Earning Date
- PD 05-29-2025
- VRDN 08-07-2025
- Dividend Yield
- PD N/A
- VRDN N/A
- EPS Growth
- PD N/A
- VRDN N/A
- EPS
- PD N/A
- VRDN N/A
- Revenue
- PD $476,132,000.00
- VRDN $302,000.00
- Revenue This Year
- PD $9.60
- VRDN N/A
- Revenue Next Year
- PD $7.56
- VRDN $17,102.33
- P/E Ratio
- PD N/A
- VRDN N/A
- Revenue Growth
- PD 8.55
- VRDN 4.86
- 52 Week Low
- PD $13.92
- VRDN $9.90
- 52 Week High
- PD $23.12
- VRDN $27.20
- Technical
- Relative Strength Index (RSI)
- PD 35.97
- VRDN 52.51
- Support Level
- PD $14.26
- VRDN $14.31
- Resistance Level
- PD $16.49
- VRDN $16.05
- Average True Range (ATR)
- PD 0.59
- VRDN 0.81
- MACD
- PD -0.14
- VRDN -0.02
- Stochastic Oscillator
- PD 0.39
- VRDN 42.91
About PD PagerDuty Inc.
PagerDuty Inc is a digital operations management platform that manages urgent and mission-critical work for a modern, digital business. Its PagerDuty Operations Cloud combines artificial intelligence (AI) operations (AIOps), automation, customer service operations, and incident management with a generative AI assistant to create a flexible, resilient, and scalable platform to protect revenue and improve customer experience, improve operational efficiency, and mitigate the risk of operational failures. The company generates revenue predominantly from cloud-hosted software subscription fees and term-license software subscription fees. Geographically, the firm derives a majority of its revenue from the United States and the rest from International markets.
About VRDN Viridian Therapeutics Inc.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).